278 results on '"Rayman, Patricia"'
Search Results
2. Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival
3. Table S6 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
4. Figure S4 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
5. Supplementary Table S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
6. Supplementary Figure S5 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
7. Data from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
8. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma
9. Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
10. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy
11. Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ
12. Ifit2 restricts murine coronavirus spread to the spinal cord white matter and its associated myelin pathology
13. Topological heterogeneity of genomic and immunologic effects from combination immunotherapy treatment in the neoadjuvant setting for renal cell carcinoma (RCC).
14. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
15. Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression
16. Data from Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs
17. Supplementary Figure 1 from Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs
18. Supplementary Table from Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs
19. Supplementary Figures 2-4 from Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs
20. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
21. Supplementary Tables S1-S2 from Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
22. Supplementary Figure 1 from GM1 and Tumor Necrosis Factor-α, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
23. Data from Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
24. Supplementary Table 1 from Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
25. Data from GM1 and Tumor Necrosis Factor-α, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
26. Data from GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells
27. Supplementary Figure Legend from GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells
28. Supplementary Figure 1 from GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells
29. Abstract P1-04-04: A multiomic approach to the identification of immune signatures of anti-PD1/PDL1 therapy responders in metastatic triple negative breast cancer: new implications in the role of helper T-cell and B-cell interplay
30. Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma
31. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
32. Alterations in T-Cell Signaling Pathways and Increased Sensitivity to Apoptosis
33. Mechanisms of Immune Dysfunction in Renal Cell Carcinoma
34. Molecular Mechanisms of Immune Dysfunction in Renal Cell Carcinoma
35. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes
36. Ifit2 regulates murine-coronavirus spread to the spinal cord white matter and its associated myelin pathology
37. Longitudinal immunological responses of COVID-19 vaccination in patients with solid tumors on active treatment: A pilot study.
38. Impaired Signal Transduction in Tumor Infiltrating T Cells from Patients with Renal Cell Carcinoma
39. Immunological correlates of response and immune-mediated toxicity in checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts).
40. Quantification of Carbonic Anhydrase IX Expression in Serum and Tissue of Renal Cell Carcinoma Patients Using Enzyme-linked Immunosorbent Assay: Prognostic and Diagnostic Potentials
41. Immune Checkpoint Inhibitors (ICI) Enhance Cancer Associated Thrombosis (CAT) in Murine Model of Colon Carcinoma
42. PD33-08 PAZOPANIB, SUNITINIB, AND AXITINIB REDUCE EXPANSION OF IN VITRO INDUCED SUPPRESSIVE MACROPHAGES
43. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy
44. GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial
45. Ifit2 deficiency restricts microglial activation and leukocyte migration following murine coronavirus (m-CoV) CNS infection
46. Targeting the immunosuppressive tumor microenvironment: Synergistic effect of low-dose IL12 in combination with dual immune checkpoint inhibition in a preclinical model of ovarian cancer.
47. Renal cell carcinoma-derived gangliosides suppress nuclear factor-κB activation in T cells
48. Alterations in NFκB Activation in T Lymphocytes of Patients With Renal Cell Carcinoma
49. Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade
50. ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.